Impact of AYUSH 64 as an adjunctive to standard of care in mild COVID 19 - An open-label randomized controlled pilot study
Open Access
- 18 May 2022
- journal article
- research article
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 13 (3) , 100587
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- In silico evaluation of the compounds of the ayurvedic drug, AYUSH-64, for the action against the SARS-CoV-2 main proteaseJournal of Ayurveda and Integrative Medicine, 2022
- Ayurvedic clinical profile of COVID-19 – A preliminary reportJournal of Ayurveda and Integrative Medicine, 2022
- AYUSH 64, a polyherbal Ayurvedic formulation in Influenza-like illness - Results of a pilot studyJournal of Ayurveda and Integrative Medicine, 2022
- Add-on Ayurveda Treatment for Early Stage COVID-19: A Single Center Retrospective Cohort Study From Gujarat, IndiaJournal of Evidence-Based Integrative Medicine, 2021
- Global research trends at the intersection of coronavirus disease 2019 (COVID-19) and traditional, integrative, and complementary and alternative medicine: a bibliometric analysisBMC Complementary Medicine and Therapies, 2020
- Hyperferritinemia in critically ill COVID-19 patients – Is ferritin the product of inflammation or a pathogenic mediator?Clinica Chimica Acta, 2020
- D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control studyJournal of Intensive Care, 2020
- Ferritin levels and COVID-19Revista Panamericana de Salud Pública, 2020
- Plasma CRP level is positively associated with the severity of COVID-19Annals of Clinical Microbiology and Antimicrobials, 2020
- Biological Effects of Caesalpinia crista Seed Extracts on Helicoverpa armigera (Lepidoptera: Noctuidae) and Its Predator, Coccinella septumpunctata (Coleoptera: Coccinellidae)Journal of Asia-Pacific Entomology, 2006